Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus induction chemotherapy for locally advanced nasopharyngeal carcinoma
ChiCTR2600122114Phase 2Not yet recruiting
- Sponsor
- First Hospital of Nanping
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in nasopharyngeal carcinoma (NPC), sponsored by First Hospital of Nanping. Primary endpoint: Image complete remission rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600122114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122114.